ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib

ESMO Open. 2021 Feb;6(1):100018. doi: 10.1016/j.esmoop.2020.100018. Epub 2020 Dec 15.

Authors

M Lambertini¹, K Punie²

Affiliations

¹ Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. Electronic address: matteo.lambertini@unige.it.
² Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Camptothecin / analogs & derivatives
Camptothecin / therapeutic use*
Female
Humans
Immunoconjugates*
Thiazoles

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Immunoconjugates
Thiazoles
Alpelisib
sacituzumab govitecan
Camptothecin